Ani Pharmaceuticals (ANIP) Non-Current Debt (2012 - 2026)
Ani Pharmaceuticals (ANIP) posted Non-Current Debt of $286.0 million for Q1 2026, down 2.0% sequentially from $291.8 million in Q4 2025, and down 6.32% YoY from $305.3 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Non-Current Debt (2012 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Non-Current Debt for 14 years, with the latest figure at $286.0 million in Q1 2026.
- Quarterly Non-Current Debt fell 6.32% year-over-year to $286.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $286.0 million (down 6.32% YoY) and the FY2025 annual result came in at $291.8 million, down 5.59% from the prior year.
- Non-Current Debt retreated to $286.0 million in Q1 2026 per ANIP's latest filing, from $291.8 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $312.9 million in Q3 2024 and troughed at $284.4 million in Q2 2024.
- A 5-year average of $291.6 million and a median of $286.0 million in 2026 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2026: Non-Current Debt surged 69.43% in 2022, then slipped 6.32% in 2026.
- Over 5 years, Non-Current Debt stood at $285.7 million in 2022, then declined by 0.3% to $284.8 million in 2023, then gained by 8.53% to $309.1 million in 2024, then fell by 5.59% to $291.8 million in 2025, then retreated by 2.0% to $286.0 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $286.0 million, $291.8 million, and $297.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 130.00 Mn |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 280.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 280.16 Mn |
| Mar 31, 2026 | 286.00 Mn |
| Dec 31, 2025 | 291.84 Mn |
| Sep 30, 2025 | 297.68 Mn |
| Jun 30, 2025 | 301.48 Mn |
| Mar 31, 2025 | 305.29 Mn |
| Dec 31, 2024 | 309.11 Mn |
| Sep 30, 2024 | 312.92 Mn |
| Jun 30, 2024 | 284.39 Mn |
| Mar 31, 2024 | 284.61 Mn |
| Dec 31, 2023 | 284.82 Mn |
| Sep 30, 2023 | 285.03 Mn |
| Jun 30, 2023 | 285.24 Mn |
| Mar 31, 2023 | 285.46 Mn |
| Dec 31, 2022 | 285.67 Mn |
| Sep 30, 2022 | 285.88 Mn |
| Jun 30, 2022 | 286.10 Mn |
| Mar 31, 2022 | 286.31 Mn |
| Dec 31, 2021 | 286.52 Mn |
| Sep 30, 2021 | 186.06 Mn |